{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:17:22Z","timestamp":1792873042120,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720180051"],"award-info":[{"award-number":["20720180051"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773600"],"award-info":[{"award-number":["81773600"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008865","name":"Xiamen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.ejmech.2022.114849","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T06:03:38Z","timestamp":1665727418000},"page":"114849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77"],"prefix":"10.1016","volume":"244","author":[{"given":"Jingbo","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weirong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongzhen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaojuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingkun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3205-9037","authenticated-orcid":false,"given":"Meijuan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114849_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hep.29789","article-title":"cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentiation","volume":"68","author":"Brunt","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2022.114849_bib2","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries, CA-cancer","volume":"71","author":"Sung","year":"2021","journal-title":"J. Clin."},{"key":"10.1016\/j.ejmech.2022.114849_bib3","article-title":"Therapy of primary liver cancer","volume":"1","author":"Feng","year":"2020","journal-title":"Innovation"},{"key":"10.1016\/j.ejmech.2022.114849_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2022.114849_bib5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114849_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114849_bib7","first-page":"688","article-title":"Safety, pharmacokinetics and efficacy of donafenib in treating advanced hepatocellular carcinoma: report from a phase 1b trial","volume":"74","author":"Liu","year":"2019","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejmech.2022.114849_bib8","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41571-018-0073-4","article-title":"Molecular therapies and precision medicine for hepatocellular carcinoma","volume":"15","author":"Llovet","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2022.114849_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","article-title":"Hepatocellular carcinoma","volume":"391","author":"Forner","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114849_bib10","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1038\/s41467-019-12606-7","article-title":"Genome-wide CRISPR\/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC","volume":"10","author":"Wei","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114849_bib11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2019.01.004","article-title":"Hepatocellular carcinoma: etiology and current and future drugs","volume":"9","author":"Jindal","year":"2019","journal-title":"J. Clin. Exp. Hepatol."},{"key":"10.1016\/j.ejmech.2022.114849_bib12","doi-asserted-by":"crossref","first-page":"8444","DOI":"10.1073\/pnas.85.22.8444","article-title":"A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily","volume":"85","author":"Hazel","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114849_bib13","doi-asserted-by":"crossref","first-page":"29256","DOI":"10.1074\/jbc.M502606200","article-title":"Induction of NR4A orphan nuclear receptor expression in macrophages in response to inflammatory stimuli","volume":"280","author":"Pei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/MOL.0b013e3283643eac","article-title":"NR4A nuclear receptors in immunity and atherosclerosis","volume":"24","author":"Hamers","year":"2013","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.ejmech.2022.114849_bib15","first-page":"4793","article-title":"Characteristics of Nur77 and its ligands as potential anticancer compounds (Review)","volume":"18","author":"Wu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2022.114849_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.steroids.2014.12.020","article-title":"Non-genomic effects of the NR4A1\/Nur77\/TR3\/NGFIB orphan nuclear receptor","volume":"95","author":"Pawlak","year":"2015","journal-title":"Steroids"},{"key":"10.1016\/j.ejmech.2022.114849_bib17","doi-asserted-by":"crossref","first-page":"6824","DOI":"10.1158\/0008-5472.CAN-10-1992","article-title":"Inactivation of the orphan nuclear receptor TR3\/Nur77 inhibits pancreatic cancer cell and tumor growth","volume":"70","author":"Lee","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114849_bib18","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0092-8674(04)00162-X","article-title":"Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77\/TR3","volume":"116","author":"Lin","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114849_bib19","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14420","article-title":"Nur77 suppresses hepatocellular carcinoma via switching glucose metabolism toward gluconeogenesis through attenuating phosphoenolpyruvate carboxykinase sumoylation","volume":"8","author":"Bian","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114849_bib20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1158\/1541-7786.MCR-14-0230","article-title":"Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis","volume":"13","author":"Hu","year":"2015","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114849_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1002\/hep.24101","article-title":"Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors","volume":"53","author":"Yang","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2022.114849_bib22","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.bcp.2011.01.005","article-title":"ERK1\/2 deactivation enhances cytoplasmic Nur77 expression level and improves the apoptotic effect of fenretinide in human liver cancer cells","volume":"81","author":"Yang","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114849_bib23","doi-asserted-by":"crossref","DOI":"10.4172\/2324-9110.1000184","article-title":"Orphan nuclear receptor TR3\/Nur77 is a specific therapeutic target for hepatic cancers","volume":"6","author":"Zeng","year":"2017","journal-title":"J. Clin. Exp. Oncol."},{"key":"10.1016\/j.ejmech.2022.114849_bib24","doi-asserted-by":"crossref","first-page":"29847","DOI":"10.18632\/oncotarget.4913","article-title":"NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3beta and Nur77 to prevent beta-catenin degradation","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2022.114849_bib25","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1021\/ol006680s","article-title":"The cytosporones, new octaketide antibiotics isolated from an endophytic fungus","volume":"2","author":"Brady","year":"2000","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2022.114849_bib26","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nchembio.106","article-title":"Cytosporone B is an agonist for nuclear orphan receptor Nur77","volume":"4","author":"Zhan","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2022.114849_bib27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.molcel.2017.03.008","article-title":"Celastrol-induced Nur77 interaction with TRAF2 alleviates inflammation by promoting mitochondrial ubiquitination and autophagy","volume":"66","author":"Hu","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114849_bib28","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1210\/me.2005-0331","article-title":"Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77","volume":"20","author":"Pei","year":"2006","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2022.114849_bib29","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1038\/s41467-021-26295-8","article-title":"Phase separation of Nur77 mediates celastrol-induced mitophagy by promoting the liquidity of p62\/SQSTM1 condensates","volume":"12","author":"Peng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2022.114849_bib30","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/mol.107.044800","article-title":"The induction of orphan nuclear receptor Nur77 expression by n-butylenephthalide as pharmaceuticals on hepatocellular carcinoma cell therapy","volume":"74","author":"Chen","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114849_bib31","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.289.5482.1159","article-title":"Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3","volume":"289","author":"Li","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114849_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3748\/wjg.v8.i3.446","article-title":"Induction of apoptosis by TPA and VP-16 is through translocation of TR3","volume":"8","author":"Liu","year":"2002","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejmech.2022.114849_bib33","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1038\/sj.onc.1210149","article-title":"6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1alpha resulting in new vessel formation","volume":"26","author":"Yoo","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114849_bib34","doi-asserted-by":"crossref","first-page":"8871","DOI":"10.1158\/0008-5472.CAN-08-1972","article-title":"Modulation of orphan nuclear receptor Nur77-mediated apoptotic pathway by acetylshikonin and analogues","volume":"68","author":"Liu","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114849_bib35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1196\/annals.1299.029","article-title":"Orphan nuclear receptor Nur77 translocates to mitochondria in the early phase of apoptosis induced by synthetic chenodeoxycholic acid derivatives in human stomach cancer cell line SNU-1","volume":"1010","author":"Jeong","year":"2003","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2022.114849_bib36","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ejps.2013.07.007","article-title":"1,1-Bis (3'-indolyl)-1-(p-substitutedphenyl)methane compounds inhibit lung cancer cell and tumor growth in a metastasis model","volume":"50","author":"Andey","year":"2013","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2022.114849_bib37","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/me.2014-1102","article-title":"Diindolylmethane analogs bind NR4A1 and are NR4A1 antagonists in colon cancer cells","volume":"28","author":"Lee","year":"2014","journal-title":"Mol. Endocrinol."},{"key":"10.1016\/j.ejmech.2022.114849_bib38","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1535-7163.MCT-18-0918","article-title":"BI1071, a novel Nur77 modulator, induces apoptosis of cancer cells by activating the Nur77-Bcl-2 apoptotic pathway","volume":"18","author":"Chen","year":"2019","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2022.114849_bib39","doi-asserted-by":"crossref","first-page":"51640","DOI":"10.1039\/C7RA08149A","article-title":"Synthesis and biological evaluation of 1-(2-(adamantane-1-yl)-1 H-indol-5-yl)-3-substituted urea\/thiourea derivatives as anticancer agents","volume":"7","author":"Hu","year":"2017","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2022.114849_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112608","article-title":"Design, synthesis, and biological evaluation of 5-((8-methoxy-2-methylquinolin-4-yl)amino)-1H-indole-2-carbohydrazide derivatives as novel Nur77 modulators","volume":"204","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105008","article-title":"Synthesis, SAR study, and bioactivity evaluation of a series of Quinoline-Indole-Schiff base derivatives: compound 10E as a new Nur77 exporter and autophagic death inducer","volume":"113","author":"Li","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105651","article-title":"Discovery of a Nur77-mediated cytoplasmic vacuolation and paraptosis inducer (4-PQBH) for the treatment of hepatocellular carcinoma","volume":"121","author":"Li","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib43","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/14728222.2012.680958","article-title":"Nur77: a potential therapeutic target in cancer","volume":"16","author":"To","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2022.114849_bib44","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.289.5482.1159","article-title":"Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3","volume":"289","author":"Li","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114849_bib45","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1517\/14728222.11.1.69","article-title":"Targeting Nur77 translocation","volume":"11","author":"Zhang","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2022.114849_bib46","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmech.2019.05.009","article-title":"SAR study of celastrol analogs targeting Nur77-mediated inflammatory pathway","volume":"177","author":"Chen","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib47","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1021\/jm0306430","article-title":"Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy","volume":"47","author":"Friesner","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114849_bib48","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1021\/jm050540c","article-title":"Novel procedure for modeling ligand\/receptor induced fit effects","volume":"49","author":"Sherman","year":"2006","journal-title":"J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422007516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:53:09Z","timestamp":1759330389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422007516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":48,"alternative-id":["S0223523422007516"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114849","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 5-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)-1H-indole-2-carboxamide derivatives as novel anti-cancer agents targeting Nur77","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114849"}}